Your browser doesn't support javascript.
loading
Physiologically-based pharmacokinetic modeling for investigating the effect of simeprevir on concomitant drugs and an endogenous biomarker of OATP1B.
Nakayama, Shinji; Toshimoto, Kota; Yamazaki, Shinji; Snoeys, Jan; Sugiyama, Yuichi.
Affiliation
  • Nakayama S; DMPK Research Laboratories, Shoyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Yokohama, Kanagawa, Japan.
  • Toshimoto K; Systems Pharmacology, Non-Clinical Biomedical Science, Applied Research and Operations, Astellas Pharma Inc., Ibaraki, Japan.
  • Yamazaki S; Sugiyama Laboratory, RIKEN Cluster for Science, RIKEN, Yokohama, Kanagawa, Japan.
  • Snoeys J; Drug Metabolism and Pharmacokinetics, Janssen Research and Development, LLC, San Diego, California, USA.
  • Sugiyama Y; Drug Metabolism and Pharmacokinetics, Janssen Research and Development, Beerse, Belgium.
CPT Pharmacometrics Syst Pharmacol ; 12(10): 1461-1472, 2023 10.
Article in En | MEDLINE | ID: mdl-37667529
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: Hepatitis C / Simeprevir Limits: Humans Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: Hepatitis C / Simeprevir Limits: Humans Language: En Journal: CPT Pharmacometrics Syst Pharmacol Year: 2023 Document type: Article